Medivation Inc. has rejected a second, $1bn higher buyout offer from Sanofi, but the Xtandi (enzalutamide) developer and the French big pharma have agreed to negotiate confidentially, putting Sanofi on equal footing with other potential bidders.
San Francisco-based Medivation gained 1.3% in after-hours trading on July 5, reaching $62.56 per share, following the company's announcement that...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
